Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma
Authors:
- Luca ParuzzoLPLuca Paruzzo
- Khashayar EshaghiKEKhashayar Eshaghi
- Guido GhilardiGGGuido Ghilardi
- Abigail DoucetteADAbigail Doucette
- Matthew HoMHMatthew Ho
- Alberto CarturanACAlberto Carturan
- Dan T. VoglDVDan T. Vogl
- Adam J. WaxmanAWAdam J. Waxman
- Shivani KapurSKShivani Kapur
- Eugenio FardellaEFEugenio Fardella
- Martina PucilloMPMartina Pucillo
- Antonio ImparatoAIAntonio Imparato
Open Access
- 16 July 2025
- journal article
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 1 (2)
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Chimeric Antigen Receptor T-Cell Access in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Association of Access with Social Determinants of Health and Travel Time to Treatment CentersTransplantation and Cellular Therapy, 2024
- Bringing CAR T cell therapy trials to underserved populationsCancer Cell, 2023
- Disparities in Travel-Related Barriers to Accessing Health Care From the 2017 National Household Travel SurveyJAMA Network Open, 2023
- Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple MyelomaJAMA Network Open, 2022
- Demographic differences among patients treated with chimeric antigen receptor T‐cell therapy in the United StatesCancer Medicine, 2022
- Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant NeoplasmsJAMA Network Open, 2022
- Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy AccessTransplantation and Cellular Therapy, 2022
- Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort studyBlood Cancer Journal, 2022
- Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administrationeJHaem, 2021
- Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of CareAdvances in Therapy, 2021